Selpercatinib (LOXO-292)

Selpercatinib, a RET-inhibitor for children with solid tumours and brain tumours

Phase 1/2 Study of the Oral RET Inhibitor LOXO-292 in Pediatric Patients with Advanced RET-Altered Solid or Primary Central Nervous System Tumors



In this clinical trial children, adolescents and young adults between 12 and 21 years will be treated with Selpercatinib (Loxo-292).

Selpercatinib specifically inhibits the Receptor-Tyrosine Kinase (RET), meaning it blocks a type of enzyme (kinase) and helps to prevent the cancer cells from growing. Before the treatment starts, the identification of a RET gene alteration must be determined using laboratory testing. Therefore, only advanced tumours with RET-alterations  after standard therapy are eligible

Selpercatinib is taken orally over a 28-day cycle as gelatine capsules or as a liquid suspension.

Main inclusion criteria

  • Age: 12 to 21 years
  • advanced solid tumors or primary tumors of the central nervous system
  • Confirmed alteration of the RET-gene (mutations and fusions)
  • Karnofsky or Lansky > 50


Loxo Oncology Inc., wholly owned subsidiary of Eli Lilly and Company

Diese Webseite verwendet Cookies. Durch die Nutzung der Webseite stimmen Sie der Verwendung von Cookies zu. Datenschutzinformationen